A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II
A Randomized, Double-blind, Placebo-controlled, Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II
Sponsor: KalVista Pharmaceuticals, Ltd.
This PHASE2 trial investigates Hereditary Angioedema and is currently completed. KalVista Pharmaceuticals, Ltd. leads this study, which shows 14 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Jun 2025 — Sep 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Jun 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE2
▶ Show 9 earlier versions
-
Feb 2021 — Mar 2023 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2020 — Nov 2020 [monthly]
Recruiting PHASE2
-
Jul 2020 — Sep 2020 [monthly]
Recruiting PHASE2
-
May 2020 — Jul 2020 [monthly]
Recruiting PHASE2
-
Mar 2020 — May 2020 [monthly]
Recruiting PHASE2
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE2
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE2
First recorded
Jul 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- KalVista Pharmaceuticals, Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .